T-cell therapy (Boston 3T Biotechnologies)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameT-cell therapy (Boston 3T Biotechnologies)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT-cell receptor agonists
TargetsT-cell receptor
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoston 3t Biotechnologies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoston 3t Biotechnologies
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A